Biblio

Found 358 results
Author Keyword Title Type [ Year(Asc)]
2013
G. A. Martin, Redondo, A., Jurado, M., De Juan, A., Romero, I., Bover, I., Del Campo, J. M., Cervantes, A., Garcia, Y., Lopez-Guerrero, J. A., Mendiola, C., Palacios, J., Rubio, M. J., and A. Velasco, P., GEICO (Spanish Group for Investigation on Ovarian Cancer) treatment guidelines in ovarian cancer 2012, Clin Transl Oncol, vol. 15, pp. 509-25, 2013.
C. L. Creutzberg, Kitchener, H. C., Birrer, M. J., Landoni, F., Lu, K. H., Powell, M., Aghajanian, C., Edmondson, R., Goodfellow, P. J., Quinn, M., Salvesen, H. B., Thomas, G., and Meeting, G. C. I. G. Endometria, Gynecologic Cancer InterGroup (GCIG) Endometrial Cancer Clinical Trials Planning Meeting: taking endometrial cancer trials into the translational era, Int J Gynecol Cancer, vol. 23, pp. 1528-34, 2013.
F. Heitz, du Bois, A., Harter, P., Lubbe, D., Kurzeder, C., Vergote, I. B., Plante, M., and Pfisterer, J., Impact of beta blocker medication in patients with platinum sensitive recurrent ovarian cancer-a combined analysis of 2 prospective multicenter trials by the AGO Study Group, NCIC-CTG and EORTC-GCG., Gynecol Oncol, vol. 129, no. 3, pp. 463-6, 2013.
B. J. Monk, Pujade-Lauraine, E., and Burger, R. A., Integrating bevacizumab into the management of epithelial ovarian cancer: the controversy of front-line versus recurrent disease., Ann Oncol, vol. 24 Suppl 10, p. x58, 2013.
N. Katsumata, Yasuda, M., Isonishi, S., Takahashi, F., Michimae, H., Kimura, E., Aoki, D., Jobo, T., Kodama, S., Terauchi, F., Sugiyama, T., Ochiai, K., and Group, J. Gynecologi, Long-term results of dose-dense paclitaxel and carboplatin versus conventional paclitaxel and carboplatin for treatment of advanced epithelial ovarian, fallopian tube, or primary peritoneal cancer (JGOG 3016): a randomised, controlled, open-label trial, Lancet Oncol, vol. 14, pp. 1020-6, 2013.
S. Banerjee, Rustin, G. J. S., Paul, J., Williams, C., Pledge, S., Gabra, H., Skailes, G., Lamont, A., Hindley, A., Goss, G., Gilby, E., Hogg, M., Harper, P., Kipps, E., Lewsley, L. A., Hall, M., Vasey, P. A., and Kaye, S. B., A multicenter, randomized trial of flat dosing versus intrapatient dose escalation of single-agent carboplatin as first-line chemotherapy for advanced ovarian cancer: an SGCTG (SCOTROC 4) and ANZGOG study on behalf of GCIG., Ann Oncol, vol. 24, no. 3, p. 687, 2013.
D. Handolias, Quinn, M., Foo, S., Mileshkin, L. R., Grant, P., Dutu, G., and Rischin, D., Oral cyclophosphamide in recurrent ovarian cancer, Asia Pac J Clin Oncol, 2013.
K. D. Steffensen, Waldstrom, M., Pallisgard, N., Lund, B., Bergfeldt, K., Wihl, J., Keldsen, N., Marth, C., Vergote, I. B., and Jakobsen, A., Panitumumab and pegylated liposomal doxorubicin in platinum-resistant epithelial ovarian cancer with KRAS wild-type: the PaLiDo study, a phase II nonrandomized multicenter study, Int J Gynecol Cancer, vol. 23, pp. 73-80, 2013.
J. F. Liu, Tolaney, S. M., Birrer, M. J., Fleming, G. F., Buss, M. K., Dahlberg, S. E., Lee, H., Whalen, C., Tyburski, K., Winer, E., Ivy, P., and Matulonis, U. A., A Phase 1 trial of the poly(ADP-ribose) polymerase inhibitor olaparib (AZD2281) in combination with the anti-angiogenic cediranib (AZD2171) in recurrent epithelial ovarian or triple-negative breast cancer, Eur J Cancer, vol. 49, pp. 2972-8, 2013.
F. A. Raja, Counsell, N., Colombo, N., Pfisterer, J., du Bois, A., Parmar, M. K. B., Vergote, I. B., Gonzalez-Martin, A., Alberts, D. S., Plante, M., Torri, V., and Ledermann, J. A., Platinum versus platinum-combination chemotherapy in platinum-sensitive recurrent ovarian cancer: a meta-analysis using individual patient data., Ann Oncol, vol. 24, no. 12, pp. 3028-34, 2013.
B. Weber, Largillier, R., Ray-Coquard, I., Yazbek, G., Meunier, J., Alexandre, J., Dauba, J., Spaeth, D., Delva, R., Joly, F., Pujade-Lauraine, E., Copel, L., and France, G. I. N. E. C. O. Group, A potentially neuroprotective role for erythropoietin with paclitaxel treatment in ovarian cancer patients: a prospective phase II GINECO trial, Support Care Cancer, vol. 21, pp. 1947-54, 2013.
C. Khoon Lee, Simes, R. J., Brown, C., Gebski, V., Pfisterer, J., Swart, A. Marie, Berton-Rigaud, D., Plante, M., Skeie-Jensen, T., Vergote, I. B., Schauer, C., Pisano, C., Parma, G., Baumann, K. H., Ledermann, J. A., Pujade-Lauraine, E., Bentley, J., Kristensen, G. B., Belau, A., Nankivell, M., Canzler, U., Lord, S. J., Kurzeder, C., and Friedlander, M. Leonard, A prognostic nomogram to predict overall survival in patients with platinum-sensitive recurrent ovarian cancer., Ann Oncol, vol. 24, no. 4, p. 943, 2013.
E. Greimel, Kristensen, G. B., van der Burg, M. E. L., Coronado, P., Rustin, G. J. S., del Rio, A. Sanchez, Reed, N. Simon, Nordal, R. R., Coens, C., and Vergote, I. B., Quality of life of advanced ovarian cancer patients in the randomized phase III study comparing primary debulking surgery versus neo-adjuvant chemotherapy., Gynecol Oncol, vol. 131, no. 2, pp. 437-44, 2013.
D. Stark, Nankivell, M., Pujade-Lauraine, E., Kristensen, G. B., Elit, L., Stockler, M., Hilpert, F., Cervantes, A., Brown, J., Lanceley, A., Velikova, G., Sabate, E., Pfisterer, J., Carey, M. S., Beale, P., Qian, W., Swart, A. Marie, Oza, A. M., and Perren, T. J., Standard chemotherapy with or without bevacizumab in advanced ovarian cancer: quality-of-life outcomes from the International Collaboration on Ovarian Neoplasms (ICON7) phase 3 randomised trial., Lancet Oncol, vol. 14, no. 3, p. 243, 2013.
B. You, Colomban, O., Heywood, M., Lee, C., Davy, M., Reed, N. Simon, Pignata, S., Varsellona, N., Emons, G., Rehman, K., Steffensen, K. Dahl, Reinthaller, A., Pujade-Lauraine, E., and Oza, A. M., The strong prognostic value of KELIM, a model-based parameter from CA 125 kinetics in ovarian cancer: data from CALYPSO trial (a GINECO-GCIG study)., Gynecol Oncol, vol. 130, no. 2, p. 294, 2013.
2012
J. Alexandre, Brown, C., Coeffic, D., Raban, N., Pfisterer, J., Maenpaa, J. U., Chalchal, H., Fitzharris, B., Volgger, B., Vergote, I. B., Pisano, C., Ferrero, A., and Pujade-Lauraine, E., CA-125 can be part of the tumour evaluation criteria in ovarian cancer trials: experience of the GCIG CALYPSO trial., Br J Cancer, vol. 106, no. 4, p. 637, 2012.
L. Gladieff, Ferrero, A., De Rauglaudre, G., Brown, C., Vasey, P. A., Reinthaller, A., Pujade-Lauraine, E., Reed, N. Simon, Lorusso, D., Siena, S., Helland, H., Elit, L., and Mahner, S., Carboplatin and pegylated liposomal doxorubicin versus carboplatin and paclitaxel in partially platinum-sensitive ovarian cancer patients: results from a subset analysis of the CALYPSO phase III trial., Ann Oncol, vol. 23, no. 5, pp. 1185-9, 2012.
J. - E. Kurtz, Freyer, G., Joly, F., Gladieff, L., Kaminsky, M. C., Fabbro, M., Floquet, A., Hardy-Bessard, A. C., Raban, N., Ray-Coquard, I., Pujade-Lauraine, E., and France, G. I. N. E. C. O. Group, Combined oral topotecan plus carboplatin in relapsed or advanced cervical cancer: a GINECO phase I-II trial, Anticancer Res, vol. 32, pp. 1045-9, 2012.
S. Sagae, Aoki, D., Susumu, N., Okamoto, A., Aotani, E., Takeuchi, M., and Mandai, M., [Current movement in global clinical trials–discussion at Gynecologic Cancer Intergroup (GCIG)], Nihon Rinsho, vol. 70 Suppl 4, pp. 59-66, 2012.
A. Casado, Penninckx, B., Reed, N. Simon, van der Burg, M. E. L., Berns, E. M. J. J., Katsaros, D., Ferrero, A., Fernando, M., Jimeno, A., Vermorken, J. B., Pecorelli, S., and Vergote, I. B., EORTC Gynecological Cancer Group on the frontline of practice-changing clinical trials. , European Journal Cancer , vol. 10, no. 1, p. 73, 2012.
T. Toita, Kitagawa, R., Hamano, T., Umayahara, K., Hirashima, Y., Aoki, Y., Oguchi, M., Mikami, M., Takizawa, K., and Group, C. Cancer Vul, Feasibility and acute toxicity of Concurrent Chemoradiotherapy (CCRT) with high-dose rate intracavitary brachytherapy (HDR-ICBT) and 40-mg/m2 weekly cisplatin for Japanese patients with cervical cancer: results of a Multi-Institutional Phase 2 Study (JGOG, Int J Gynecol Cancer, vol. 22, pp. 1420-6, 2012.
U. Wagner, Marth, C., Largillier, R., Kaern, J., Brown, C., Heywood, M., Bonaventura, T., Vergote, I. B., Piccirillo, M. C., Fossati, R., Gebski, V., and Lauraine, E. P., Final overall survival results of phase III GCIG CALYPSO trial of pegylated liposomal doxorubicin and carboplatin vs paclitaxel and carboplatin in platinum-sensitive ovarian cancer patients., Br J Cancer, vol. 107, no. 4, p. 591, 2012.
K. Lindemann, Christensen, R. D., Vergote, I. B., Stuart, G. C. E., Izquierdo, M. A., Kærn, J., Havsteen, H., Eisenhauer, E., Ridderheim, M., Lopez, A. B., Hirte, H., Åvall-Lundqvist, E., Vrdoljak, E., Green, J. A., and Kristensen, G. B., First-line treatment of advanced ovarian cancer with paclitaxel/carboplatin with or without epirubicin (TEC versus TC)--a gynecologic cancer intergroup study of the NSGO, EORTC GCG and NCIC CTG., Ann Oncol, vol. 23, no. 10, pp. 2613-9, 2012.
M. Brundage, Gropp, M., Mefti, F., Mann, K., Lund, B., Gebski, V., Wolfram, G., Reed, N. Simon, Pignata, S., Ferrero, A., Brown, C., Eisenhauer, E., and Pujade-Lauraine, E., Health-related quality of life in recurrent platinum-sensitive ovarian cancer--results from the CALYPSO trial., Ann Oncol, vol. 23, no. 8, p. 2027, 2012.
L. C. Hanker, Loibl, S., Burchardi, N., Pfisterer, J., Meier, W., Pujade-Lauraine, E., Ray-Coquard, I., Sehouli, J., Harter, P., du Bois, A., ,, and Group, G. I. N. E. C. O. Study, The impact of second to sixth line therapy on survival of relapsed ovarian cancer after primary taxane/platinum-based therapy, Ann Oncol, vol. 23, pp. 2605-12, 2012.

Pages